Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 14, 2026, 9:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–47 of 23 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: HSV-2 Clear all
Completed Phase 2 Interventional

Dose Ranging Safety and Efficacy of Therapeutic HSV-2 Vaccine

NCT02114060
View directory record Official record
Conditions
Genital Herpes Simplex Type 2
Interventions
GEN-003 Vaccine (30μg of each antigen), GEN-003 Vaccine (60μg of each antigen), Matrix-M2 Adjuvant (25μg), Matrix-M2 Adjuvant (50μg), Matrix-M2 Adjuvant (75μg), Placebo
Biological
Lead sponsor
Genocea Biosciences, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
16
States / cities
Birmingham, Alabama • San Diego, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2017 · Synced Sep 14, 2026, 9:46 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

HerpeSelect® Express Rapid Test Study Protocol: Sexually Active Adult Population

NCT00655434
View directory record Official record
Conditions
Herpes Simplex Virus 2
Interventions
Not listed
Lead sponsor
Focus Diagnostics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Burbank, California
Source: ClinicalTrials.gov public record
Updated Jan 8, 2009 · Synced Sep 14, 2026, 9:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

VivaGel™ in Healthy Young Women

NCT00331032
View directory record Official record
Conditions
Herpes Simplex II
Interventions
3% w/w SPL7013 Gel, Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 24 Years · Female only
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 22, 2013 · Synced Sep 14, 2026, 9:46 AM EDT
Completed Phase 2 Interventional

Rollover Trial for Placebo Subjects Previously Enrolled Into GEN-003-002 Study

NCT02300142
View directory record Official record
Conditions
Genital Herpes Simplex Type 2
Interventions
GEN-003 Vaccine (30μg of each antigen), GEN-003 Vaccine (60μg of each antigen), Matrix-M2 Adjuvant (25μg), Matrix-M2 Adjuvant (50μg), Matrix-M2 Adjuvant (75μg)
Biological
Lead sponsor
Genocea Biosciences, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
16
States / cities
Birmingham, Alabama • San Diego, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2017 · Synced Sep 14, 2026, 9:46 AM EDT
Completed No phase listed Observational

Long-term Follow-up of GEN-003-002 Subjects for Efficacy and Immunogenicity

NCT02910284
View directory record Official record
Conditions
Genital Herpes Simplex Type 2
Interventions
Observational
Biological
Lead sponsor
Genocea Biosciences, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
13
States / cities
Birmingham, Alabama • San Diego, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2017 · Synced Sep 14, 2026, 9:46 AM EDT
Terminated Phase 4 Interventional Results available

Effect of HSV-2 Suppressive Therapy on Sexual Behavior

NCT00495716
View directory record Official record
Conditions
Genital Herpes
Interventions
acyclovir
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 6, 2023 · Synced Sep 14, 2026, 9:46 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Serologic Assays for the Diagnosis of Herpes Simplex Virus Type 2

NCT01112956
View directory record Official record
Conditions
Genital Herpes
Interventions
Not listed
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
16 Years to 55 Years
Enrollment
2,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
3
States / cities
Baltimore, Maryland • Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 22, 2011 · Synced Sep 14, 2026, 9:46 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety and Efficacy Trial of DNA Vaccines to Treat Genital Herpes in Adults

NCT02030301
View directory record Official record
Conditions
Genital Herpes Simplex Type 2
Interventions
VCL-HB01, VCL-HM01, PBS
Biological
Lead sponsor
Vical
Industry
Eligibility
18 Years to 50 Years
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
7
States / cities
Birmingham, Alabama • Hollywood, Florida • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Sep 14, 2026, 9:46 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Safety and Efficacy of 4 Investigational HSV 2 Vaccines in Adults With Recurrent Genital Herpes Caused by HSV 2

NCT04222985
View directory record Official record
Conditions
Genital Herpes
Interventions
HSV 2 Formulation 1, HSV 2 Formulation 2, HSV 2 Formulation 3, HSV 2 Formulation 4, HSV 2 Formulation 5, HSV 2 Formulation 6, Sodium Chloride 0.9%
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
4
States / cities
Hollywood, Florida • Boston, Massachusetts • Raleigh, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2022 · Synced Sep 14, 2026, 9:46 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effect of Valacyclovir in the Reduction of HSV-2 Recurrence and Shedding

NCT00803543
View directory record Official record
Conditions
HIV, HIV Infections
Interventions
Valacyclovir, Placebo
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
103 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 12, 2017 · Synced Sep 14, 2026, 9:46 AM EDT
Completed Phase 4 Interventional Results available

Randomized Trial to Evaluate Suppressive Effect of High-Dose Acyclovir Versus Once-Daily Valacyclovir on Persons With HSV-2

NCT00362297
View directory record Official record
Conditions
Genital Herpes
Interventions
acyclovir, valacyclovir
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 17, 2021 · Synced Sep 14, 2026, 9:46 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes

NCT06033261
View directory record Official record
Conditions
Genital Herpes
Interventions
mRNA-1608, BEXSERO
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
303 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
23
States / cities
Birmingham, Alabama • Tucson, Arizona • Beverly Hills, California + 20 more
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Sep 14, 2026, 9:46 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Herpes Simplex Type 2 Co-infection in Veterans With Chronic Hepatitis C

NCT01037621
View directory record Official record
Conditions
Hepatitis C Virus Infection, Infection, Herpesvirus 2, Human
Interventions
Valacyclovir
Drug
Lead sponsor
G.V. (Sonny) Montgomery VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Nov 6, 2011 · Synced Sep 14, 2026, 9:46 AM EDT
Completed Phase 4 Interventional Results available

Randomized Trial to Evaluate Suppressive Effect of High-Dose Valacyclovir Versus Once-Daily Valacyclovir on Persons With HSV-2

NCT01346475
View directory record Official record
Conditions
Genital Herpes
Interventions
Valacyclovir
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 8, 2017 · Synced Sep 14, 2026, 9:46 AM EDT
Completed No phase listed Observational Results available

Comparative Effectiveness of Treatment Options for Genital Herpes Infection to Reduce Adverse Pregnancy Outcomes

NCT02986802
View directory record Official record
Conditions
HSV-2 Infection, PreTerm Birth, Pregnancy Complications
Interventions
Not listed
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older · Female only
Enrollment
89,132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Sep 16, 2021 · Synced Sep 14, 2026, 9:46 AM EDT
Withdrawn No phase listed Observational

NOWDx Test for the Diagnosis of Herpes Simplex Virus Type 2

NCT04294030
View directory record Official record
Conditions
HSV-2 Infection, Herpes Simplex Virus Infection
Interventions
Diagnostic Test: NOWDx HSV-2 Test
Device
Lead sponsor
NOWDiagnostics, Inc.
Industry
Eligibility
18 Years to 64 Years
Timeline
2023
U.S. locations
3
States / cities
Tempe, Arizona • Coral Gables, Florida • Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Sep 14, 2026, 9:46 AM EDT
Completed Phase 4 Interventional Results available

VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2

NCT00306293
View directory record Official record
Conditions
Herpes Labialis
Interventions
valacyclovir
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
18
States / cities
Anaheim, California • Carmichael, California • Fair Oaks, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2018 · Synced Sep 14, 2026, 9:46 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study on the Reactogenicity, Safety and Immune Response of a Vaccine Against Herpes Simplex Virus (HSV)-2 in Healthy Participants Aged 18-40 Years

NCT04762511
View directory record Official record
Conditions
Herpes Simplex
Interventions
Lower dose formulation of HSV vaccine (GSK4108771A), Low dose formulation of HSV vaccine (GSK4108771A), Medium dose formulation of HSV vaccine (GSK4108771A), High dose formulation of HSV vaccine (GSK4108771A), Placebo (saline)
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 40 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
2
States / cities
Lenexa, Kansas • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 27, 2021 · Synced Sep 14, 2026, 9:46 AM EDT
Completed No phase listed Observational

An Epidemiological Study to Assess Performance of Using Healthcare Tools to Understand Genital Herpes Simplex Virus-2 (HSV-2) in Patients ≥ 18 Years of Age in the United States and Europe.

NCT04950712
View directory record Official record
Conditions
Herpes Genitalis
Interventions
Blood sampling, Anogenital lesion swab collection
Procedure
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
537 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
22
States / cities
Long Beach, California • Los Angeles, California • San Francisco, California + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Sep 14, 2026, 9:46 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Herpevac Neonatal Substudy

NCT00138320
View directory record Official record
Conditions
Herpes Simplex
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 30 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
5
States / cities
Baltimore, Maryland • St Louis, Missouri • Rochester, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2013 · Synced Sep 14, 2026, 9:46 AM EDT
Completed Phase 2 Interventional Results available

Biological Efficacy Study of HerpV Vaccine With QS-21 to Treat Participants With Recurrent Genital Herpes

NCT01687595
View directory record Official record
Conditions
Herpes Simplex Type 2
Interventions
HerpV and QS-21, Placebo
Drug
Lead sponsor
Agenus Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
5
States / cities
Portland, Oregon • Houston, Texas • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 12, 2021 · Synced Sep 14, 2026, 9:46 AM EDT
Completed Phase 4 Interventional Results available

A Study Comparing Daily Treatment With Valaciclovir To Placebo For Suppression Of Herpes Simplex Virus HSV-2 Genital Herpes In Newly Diagnosed Patients. VALTREX® Tablet is a Trademark of the GlaxoSmithKline Group of Companies.

NCT00158860
View directory record Official record
Conditions
Herpes Genitalis
Interventions
Valaciclovir, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
384 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
58
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2019 · Synced Sep 14, 2026, 9:46 AM EDT
Completed Phase 4 Interventional Results available

Trial to Study the Effect of Dose of Herpes Simplex Virus-2 (HSV-2) Suppressive Therapy on HSV and HIV

NCT00527618
View directory record Official record
Conditions
Genital Herpes, HIV Infection
Interventions
valacyclovir, acyclovir
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Sep 14, 2026, 9:46 AM EDT